Systemic diseases in myelodysplastic syndromes.

被引:18
|
作者
Hebbar, M
HebbarSavean, K
Fenaux, P
机构
来源
REVUE DE MEDECINE INTERNE | 1995年 / 16卷 / 12期
关键词
myelodysplastic syndrome; relapsing polychondritis; vasculitis; seronegative arthritis;
D O I
10.1016/0248-8663(96)80810-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Myelodysplastic syndromes (MDS) are characterized by quantitative and functional involvement of myeloid lineages. Yet, systemic manifestations, suggestive of a lymphocytic involvement, have been described in MDS. We review here biological and clinical data concerning the associations between MDS and immunological disorders. Biological auto-immune markers are in fact rare in MDS, and especially encountered in the chronic myelomonocytic leukemia subgroup. Only a few systemic diseases seem to be frequently associated with MDS: seronegative arthritis, cutaneous vasculitis, and relapsing polychondritis. These diseases are probably not entirely auto-immune, and the signification of their association with an MDS remains nuclear. About 30% of relapsing polychondritis are associated with MDS. Conversely, 0.6% of MDS are associated with a relapsing polychondritis. These associations are mainly encountered in men suffering from a refractory anemia (with or without excess of blasts). The main cytogenetic abnormalities are monosomy 7, presence of a ring chromosome, and monosomy 16.
引用
收藏
页码:897 / 904
页数:8
相关论文
共 50 条
  • [1] Myelodysplastic syndromes.
    Miller K.B.
    Current Treatment Options in Oncology, 2000, 1 (1) : 63 - 69
  • [2] RAS and the myelodysplastic syndromes.
    Gallagher, A
    Darley, R
    Padua, RA
    PATHOLOGIE BIOLOGIE, 1997, 45 (07): : 561 - 568
  • [3] Apoptosis in myelodysplastic syndromes.
    Pearsall, CP
    Kroft, S
    Ross, C
    Schnitzer, B
    Singleton, TP
    LABORATORY INVESTIGATION, 1997, 76 (01) : 767 - 767
  • [4] Cytogenetic of myelodysplastic syndromes.
    Lai, JL
    Fenaux, P
    PATHOLOGIE BIOLOGIE, 1997, 45 (07): : 550 - 555
  • [5] Megakaryopoiesis in myelodysplastic syndromes.
    Brereton, ML
    Adams, JA
    Briggs, M
    Yin, JAL
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 101 : 63 - 63
  • [6] Mitochondrial dysfunction in myelodysplastic syndromes.
    Reddy, PL
    Dar, S
    Anthwal, S
    Khan, M
    Patkar, K
    Rizvi, A
    Khan, T
    Azhar, O
    Nisar, D
    Shetty, VT
    Mundle, SD
    Alvi, S
    Galili, N
    Raza, A
    BLOOD, 2002, 100 (11) : 337B - 337B
  • [7] Telomere length in myelodysplastic syndromes.
    Boultwood, J
    Fidler, C
    Wainscoat, JS
    BLOOD, 1995, 86 (10) : 1325 - 1325
  • [8] Etiologic factors of myelodysplastic syndromes.
    Nisse, C
    PATHOLOGIE BIOLOGIE, 1997, 45 (07): : 539 - 544
  • [9] Editorial. Myelodysplastic syndromes.
    Fenaux, P
    PATHOLOGIE BIOLOGIE, 1997, 45 (07): : 537 - 538
  • [10] Prognostic classification in myelodysplastic syndromes.
    Sanz, GF
    Morel, P
    PATHOLOGIE BIOLOGIE, 1997, 45 (08): : 617 - 626